OLMA · Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals reported a significantly widened GAAP net loss of $53.1 million for the first quarter ended March 31, 2026, compared to $30.4 million in the prior-year quarter, driven primarily by escalated research and development expenses totaling $49.2 million, up from $30.6 million. This increase stemmed from heightened spending on late-stage clinical trials for lead candidate palazestrant (OP-1250), including the ongoing Phase 3 OPERA-02 trial in combination with ribociclib for frontline ER+/HER2- metastatic breast cancer, and early-stage advancement of OP-3136, a KAT6 inhibitor. Personnel-related costs also rose, with non-cash stock-based compensation contributing $6.6 million to R&D and $3.6 million to G&A expenses. Non-GAAP R&D expenses were $42.7 million and G&A $5.2 million, reflecting similar trends after adjustments. General and administrative expenses climbed to $8.8 million from $4.2 million due to corporate and personnel costs. Despite the losses, the company maintained a strong balance sheet with $505.3 million in cash, cash equivalents, and marketable securities as of quarter-end, supporting pipeline progress without immediate funding concerns. CEO Sean P. Bohen highlighted key catalysts: top-line data from the pivotal Phase 3 OPERA-01 monotherapy trial expected this fall, initial OP-3136 Phase 1 data at ASCO, and continued OPERA-02 enrollment. Preclinical data presented at AACR reinforced palazestrant's complete ER antagonism and synergy with OP-3136 in ER+/HER2- models. These developments position Olema for potential first commercial launch next year, transforming it into a fully integrated oncology company focused on metastatic breast cancer therapies.